



Study	Design	Population	Intervention	Comparison	Outcome	Effect Size	Significance	Notes								
Sosa, 2017 <sup>a</sup>	Cross-sectional	RA patients without FM (n=95)	NR	NR	RA patients with FM according to ACR criteria (n=35)	median (range) NR	CDAI	NA	PD 7-joint US score	NA	Same time point	r=0.37, p<0.05	r=0.01, ns	Effect of the presence of fibromyalgia on the score difference between traditional and modified composite scores, adjusted by age, sex and nodular disease, mean increment (95%CI, p-value): 1.50 (0.60-2.40, 0.001)	L/L/H/L	L/L/L
					modifiedDAS28-ESR (excluding TJC and patient's global assessment of disease activity)	NA	DAS28-ESR	NA	Same time point							
					modifiedDAS28-CRP (excluding TJC and patient's global assessment of disease activity)	NA	DAS28-CRP	NA	Same time point							
					modifiedSDAI (excluding TJC and patient's global assessment of disease activity)	NA	SDAI	NA	Same time point							
Tamas, 2017 <sup>a</sup>	Cross-sectional	RA patients treated with bDMARDs and without FM (n=30)	DAS28-CRP 3.33	NR	RA patients treated with bDMARDs and with FM (according to difference of ≥7 between TJC and SJC) (n=9)	DAS28-CRP 5.13	SJC	NA	US: GS synovitis, 7-joint US score	NA	NR	r=0.44, p=0.015	ns	Effect of the presence of fibromyalgia on the score difference between traditional and modified composite scores, adjusted by age, sex and nodular disease, mean increment (95%CI, p-value): 1.55 (0.63-2.48, 0.001)	L/L/U/U	H/L/L
					SJC	NA	US: PD synovitis, 7-joint US score	NA	NR	r=0.47, p=0.008						
					SJC	NA	US: GS tenosynovitis, 7-joint US score	NA	NR	r=0.57, p=0.001						
					SJC	NA	US: PD tenosynovitis, 7-joint US score	NA	NR	r=0.46, p=0.011						

ACR: American college of rheumatology; bDMARDs: biologic disease modifying anti-rheumatic drugs; BMI: body mass index; CDAI: clinical disease activity index; CI: confidence interval; CRP: C-reactive protein; DAS28: disease activity score assessing 28 joints; FM: fibromyalgia; GS: Gray scale; H: high; L: low; MBDA: multi-biomarker disease activity; MCP: metacarpophalangeal; MTP: metatarsophalangeal; n: number of patients; NA: not applicable; NPV: negative predictive value; NR: not reported; ns: not significant; OR: odds ratio; PD: power doppler; PIP: proximal interphalangeal; PPV: positive predictive value; RA: rheumatoid arthritis; SDAI: simplified disease activity index; SJC: swollen joint count; TJC: tender joint count; U: unclear; US: ultrasonography; Y: years

<sup>a</sup>: Conference abstract  
 1. According to QUADAS-2, assessing 4 domains: Patient selection/Index test(s)/Reference standard/Flow and timing; 2. According to QUADAS-2, assessing 3 domains: Patient selection/Index test(s)/Reference standard; \*According to AMSTAR-2, highest category as found